Zylig Lifesciences
Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.mg)
Vigroz MV 2mg/500mg/0.2mg Tablet is a combination of anti-diabetic drugs used to treat type 2 diabetes mellitus in adults, helping to control blood sugar levels.
Tablet
Vigroz MV 2mg/500mg/0.2mg Tablet is a combination of three antidiabetic medicines used to treat type 2 diabetes mellitus in adults. It helps control blood sugar levels in people with diabetes.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Vigroz MV 2mg/500mg/0.2mg Tablet is to be taken empty stomach.
No common side effects listed.
It is unsafe to consume alcohol with Vigroz MV 2mg/500mg/0.2mg Tablet.
Vigroz MV 2mg/500mg/0.2mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Vigroz MV 2mg/500mg/0.2mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Vigroz MV 2mg/500mg/0.2mg Tablet is a combination of three antidiabetic medicines.
Take it with food to lower your chance of having an upset stomach. It can cause hypoglycemia (low blood sugar level) when used with other antidiabetic medicines, alcohol or if you delay or miss a meal. Your doctor may check your liver function regularly. Inform your doctor if you develop symptoms such as abdominal pain, loss of appetite, or yellowing of the eyes or skin (jaundice).
Vigroz MV 2mg/500mg/0.2mg Tablet contains three active ingredients: Glimepiride, Metformin, and Voglibose. This combination is used to treat Type 2 diabetes mellitus (DM). It helps regulate blood glucose levels in adults when used alongside a healthy diet and regular exercise. Glimepiride increases insulin release from the pancreas, Metformin reduces glucose production by the liver and improves insulin sensitivity, while Voglibose inhibits alpha-glucosidase, lowering postprandial glucose levels after meals.
Common side effects associated with Vigroz MV 2mg/500mg/0.2mg Tablet include hypoglycemia (low blood sugar), nausea, diarrhea, altered taste, flatulence, stomach pain, headache, skin rash, and respiratory tract infection.
It is important to avoid using Vigroz MV 2mg/500mg/0.2mg Tablet if you have known allergies to any of its components or excipients, or in patients with moderate to severe kidney disease and inflammatory bowel disease, colonic ulcerations, or underlying metabolic acidosis including diabetic ketoacidosis.
No, combining Vigroz MV 2mg/500mg/0.2mg Tablet with alcohol may increase the risk of hypoglycemia and lactic acidosis.
Yes, Vigroz MV 2mg/500mg/0.2mg Tablet can cause hypoglycemia (low blood sugar level). This may manifest as nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, and feelings of anxiety or shakiness. It is more likely to occur if you miss meals, drink alcohol excessively, overexert yourself, or take other antidiabetic medications alongside it. Regular blood sugar monitoring is crucial. Always keep glucose tablets, honey, or fruit juice readily available.
Store Vigroz MV 2mg/500mg/0.2mg Tablet in its original packaging, keeping it tightly closed. Refer to the package or label for instructions on storage and disposal. Avoid letting pets, children, or others access this medication.